{"id":"NCT04436497","sponsor":"Merit E. Cudkowicz, MD","briefTitle":"HEALEY ALS Platform Trial - Regimen A Zilucoplan","officialTitle":"HEALEY ALS Platform Trial - Regimen A Zilucoplan","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2020-07-29","primaryCompletion":"2022-04-13","completion":"2022-05-04","firstPosted":"2020-06-18","resultsPosted":"2023-07-25","lastUpdate":"2023-07-25"},"enrollment":162,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Amyotrophic Lateral Sclerosis"],"interventions":[{"type":"DRUG","name":"Zilucoplan","otherNames":[]},{"type":"DRUG","name":"Matching Placebo","otherNames":[]}],"arms":[{"label":"Zilucoplan","type":"EXPERIMENTAL"},{"label":"Matching Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.\n\nRegimen A will evaluate the safety and efficacy of a single study drug, zilucoplan, in participants with ALS.","primaryOutcome":{"measure":"Disease Progression as Assessed by the ALSFRS-R Total Score","timeFrame":"Baseline through 24 Weeks","effectByArm":[{"arm":"Zilucoplan","deltaMin":-1.11,"sd":0.083},{"arm":"Matching Placebo","deltaMin":-1.03,"sd":0.072}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":25,"n":122},"commonTop":["Fall","Muscular weakness","Injection site bruising","Neuromyopathy","Fatigue"]}}